RxSight, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-11-13: Study NCT07347379; Company role Lead sponsor; Phase Observational; Status Enrolling by invitation.
- 2021-12-03: Study NCT05202808; Company role Lead sponsor; Phase Not applicable; Status Completed.
- 2020-05-22: Study NCT04529616; Company role Lead sponsor; Phase Not applicable; Status Completed.
- 2019-11-15: Study NCT04177771; Company role Lead sponsor; Phase Not applicable; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-11-13 | NCT07347379 Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study | Lead sponsor | Observational | Enrolling by invitation | Aphakia Cataract | 108 | 2026-12 |
| 2021-12-03 | NCT05202808 RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study | Lead sponsor | Not applicable | Completed Results posted | Aphakia; Cataract | 500 | 2024-12-16 |
| 2020-05-22 | NCT04529616 Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes | Lead sponsor | Not applicable | Completed Results posted | Aphakia; Cataract | 79 | 2022-10-01 |
| 2019-11-15 | NCT04177771 A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus | Lead sponsor | Not applicable | Terminated Results posted | Aphakia; Cataract; Presbyopia | 34 | 2021-12-20 |
| 2019-07-01 | NCT04005586 A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL) | Lead sponsor | Not applicable | Completed Results posted | Aphakia; Cataract | 25 | 2020-03-01 |
| 2018-08-28 | NCT03660865 Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery | Lead sponsor | Not applicable | Completed Results posted | Aphakia; Cataract | 105 | 2020-04-01 |
| 2018-06-19 | NCT03771352 Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism | Lead sponsor | Not applicable | Completed Results posted | Cataract | 55 | 2020-07-01 |
| 2018-06-14 | NCT03895034 Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes | Lead sponsor | Not applicable | Completed Results posted | Aphakia; Cataract | 66 | 2020-03-01 |
| 2018-01-26 | NCT03729024 Exploratory Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RXLAL) With The Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism | Lead sponsor | Not applicable | Completed Results posted | Aphakia; Cataract | 21 | 2020-02-04 |
| 2011-12 | NCT01496066 Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism | Lead sponsor | Not applicable | Completed Results posted | Cataract | 600 | 2016-06 |
| 2009-01 | NCT00845520 Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL) | Lead sponsor | Not applicable | Completed Results posted | Cataracts | 74 | 2013-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |